https://www.thepharmaletter.com/article/new-eu-measures-to-minimize-risk-of-meningioma-with-medicines-containing-nomegestrol-or-chlormadinone
0
0
The European Medicines Agency's (EMA) human medicines committee (CHMP) has endorsed the recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) in concluding that the benefits of medicines containing nomegestrol or chlormadinone outweigh the risks, provided new measures are taken to minimize the risk of meningioma. Medicines containing nomegestrol or ... - The Pharma Letter
9/2/22 at 1:15pm
Organization
The Pharma Letter
Authors
Details
74 words
Summarize
Health Pharmaceuticals & Biotech CHMP EMA nomegestrol meningioma chlormadinone Pharmacovigilance Risk Assessment Committee
The Pharmacovigilance Risk Assessment Committee (PRAC).  has recommended new measures to minimise the risk of meningioma with medicines containing nomegestrol o
Create an account or login to join the discussion